alert graphic is a stylized exclamation mark

Please carefully review our COVID-19 information hub for updates on IRB processes during the COVID-19 outbreak.

Participants

Skip to end of metadata
Go to start of metadata




Questions & concerns about an ongoing study

Find out about ongoing studies

Contact OHSRP



About OHSRP

Right To Try information for potential participants





Questions & concerns about an ongoing study

We plan to have a form available soon. For now, please contact us by phone at (301) 402-3713 or by email at irb@od.nih.gov. Please note, if you send information to the email above, please do not include sensitive information or personal health information.



Find out about ongoing studies

For general information and information specific to NIH trials, please visit: Participate in Clinical Studies at the NIH.

For information an all active clinical trials, please visit : https://clinicaltrials.gov/.



Contact OHSRP

Our main office is located at 6700B Rockledge Drive, Suite 4300, Bethesda, MD 20897.

You can contact OHSRP by phone (301) 402-3713 or by email (irb@od.nih.gov). Please note, if you send information to the email above, please do not include sensitive information or personal health information.



About OHSRP

The Office of Human Subjects Research Protections (OHSRP) carries out the day-to-day operations and regulatory oversight of human research activities within the Human Research Protections Program (HRPP). The OHSRP promotes the protection of rights, safety and welfare of human subjects, and the NIH’s research mandate. You can find more information on our About page.



Right To Try

Federal and state Right to Try laws generally permit the use of unapproved, experimental drugs and biological products by individuals diagnosed with a life-threatening condition who (1) have exhausted approved treatment options, and (2) are unable to participate in clinical trials involving the product.

However, NIH is a federal research agency. Therefore, it cannot provide an unapproved drug or biological product to an individual unless the subject is enrolled in an NIH protocol. Further, Right to Try laws do not establish a “right” to participate in a clinical trial or protocol, i.e., the laws do not entitle patients to participate in an NIH-sponsored clinical trial.

If you are unable to enroll in an NIH protocol involving an unapproved drug or biological product, the Right to Try Act may provide another option. Interested individuals should speak to their home-based treating physician about the possibility of receiving an unapproved drug or biological product from a source other than the NIH through the Right to Try pathway. The federal Right to Try Act became law on May 30, 2018. More information is available at https://www.congress.gov/bill/115th-congress/senate-bill/204/text.